Cargando…

The drebrin/EB3 pathway drives invasive activity in prostate cancer

Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Dart, A E, Worth, D C, Muir, G, Chandra, A, Morris, J D, McKee, C, Verrill, C, Bryant, R J, Gordon-Weeks, P R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537610/
https://www.ncbi.nlm.nih.gov/pubmed/28319065
http://dx.doi.org/10.1038/onc.2017.45
_version_ 1783254214834651136
author Dart, A E
Worth, D C
Muir, G
Chandra, A
Morris, J D
McKee, C
Verrill, C
Bryant, R J
Gordon-Weeks, P R
author_facet Dart, A E
Worth, D C
Muir, G
Chandra, A
Morris, J D
McKee, C
Verrill, C
Bryant, R J
Gordon-Weeks, P R
author_sort Dart, A E
collection PubMed
description Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression.
format Online
Article
Text
id pubmed-5537610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55376102017-08-07 The drebrin/EB3 pathway drives invasive activity in prostate cancer Dart, A E Worth, D C Muir, G Chandra, A Morris, J D McKee, C Verrill, C Bryant, R J Gordon-Weeks, P R Oncogene Original Article Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression. Nature Publishing Group 2017-07-20 2017-03-20 /pmc/articles/PMC5537610/ /pubmed/28319065 http://dx.doi.org/10.1038/onc.2017.45 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Dart, A E
Worth, D C
Muir, G
Chandra, A
Morris, J D
McKee, C
Verrill, C
Bryant, R J
Gordon-Weeks, P R
The drebrin/EB3 pathway drives invasive activity in prostate cancer
title The drebrin/EB3 pathway drives invasive activity in prostate cancer
title_full The drebrin/EB3 pathway drives invasive activity in prostate cancer
title_fullStr The drebrin/EB3 pathway drives invasive activity in prostate cancer
title_full_unstemmed The drebrin/EB3 pathway drives invasive activity in prostate cancer
title_short The drebrin/EB3 pathway drives invasive activity in prostate cancer
title_sort drebrin/eb3 pathway drives invasive activity in prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537610/
https://www.ncbi.nlm.nih.gov/pubmed/28319065
http://dx.doi.org/10.1038/onc.2017.45
work_keys_str_mv AT dartae thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT worthdc thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT muirg thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT chandraa thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT morrisjd thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT mckeec thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT verrillc thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT bryantrj thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT gordonweekspr thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT dartae drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT worthdc drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT muirg drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT chandraa drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT morrisjd drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT mckeec drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT verrillc drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT bryantrj drebrineb3pathwaydrivesinvasiveactivityinprostatecancer
AT gordonweekspr drebrineb3pathwaydrivesinvasiveactivityinprostatecancer